Horizon Scanning

It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.

The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:

  • Is this emerging technology new or replacing an existing technology?
  • Where is this technology in the FDA regulatory process?
  • When will this technology be commercially available in the market?
  • What is the projected use, cost, and financial impact of this technology?

Nanostim Leadless Pacemaker

A transcatheter, miniaturized, single-chamber, leadless cardiac pacemaker proposed to reduce risk for lead-related complications associated with conventional pacemakers.

BioFreedom Drug-Coated Stent

A polymer-free biolimus A9–coated stent for treatment of coronary artery disease in patients with high bleeding risk.

Zurampic (Lesinurad)

An oral first-in-class selective uric acid reabsorption inhibitor proposed for second-line use in combination with a xanthine oxidase inhibitor to treat hyperuricemia associated with gout.